Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tafasitamab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyte Exceeds Q1 Estimates With Strong Cancer Drug Demand
    Incyte Exceeds Q1 Estimates With Strong Cancer Drug Demand

    28 Apr 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-beats-first-quarter-estimates-strong-demand-cancer-drugs-2026-04-28/

    REUTERS
    28 Apr 2026
    Share Share
    Minjuvi for R/R Follicular Lymphoma Approved in Australia
    Minjuvi for R/R Follicular Lymphoma Approved in Australia

    23 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/minjuvi-tafasitamab-for-relapsed-or-refractory-follicular-lymphoma-approved-in-australia-302751394.html

    PR NEWSWIRE
    23 Apr 2026
    Share Share
    Incyte to Highlight Phase 3 Tafasitamab Data at ASCO 2026
    Incyte to Highlight Phase 3 Tafasitamab Data at ASCO 2026

    21 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260421480376/en/Incyte-Highlights-New-Phase-3-Tafasitamab-Data-at-the-2026-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting

    BUSINESSWIRE
    21 Apr 2026
    Share Share
    Incyte to seek FDA approval for Monjuvi in front-line DLBCL
    Incyte to seek FDA approval for Monjuvi in front-line DLBCL

    05 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260105730167/en/Incyte-Announces-Positive-Topline-Results-from-Pivotal-Study-of-Tafasitamab-MonjuviMinjuvi-as-a-First-line-Treatment-for-Diffuse-Large-B-Cell-Lymphoma

    BUSINESSWIRE
    05 Jan 2026
    Share Share
    Japan Approves Incyte's Minjuvi for R/R Follicular Lymphoma
    Japan Approves Incyte's Minjuvi for R/R Follicular Lymphoma

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251221198206/en/Incyte-Japan-Announces-Approval-of-Minjuvi-tafasitamab-in-Combination-with-Rituximab-and-Lenalidomide-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma

    BUSINESSWIRE
    22 Dec 2025
    Share Share
    EU Approves Minjuvi for Relapsed/Refractory Follicular Lymphoma
    EU Approves Minjuvi for Relapsed/Refractory Follicular Lymphoma

    17 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251217282673/en/Incyte-Announces-European-Commission-Approval-of-Minjuvi-tafasitamab-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma

    BUSINESSWIRE
    17 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.